Merck Faces China Trial Probe, Settles Gardasil Suits for $50M
MRK sits 69% above its 52-week low of $76.66.
Summary
Merck disclosed a $50 million settlement of Gardasil lawsuits while defending the vaccine's safety. Separately, U.S. lawmakers are demanding details on data protection and oversight of Merck's China-based clinical trials, specifically at Xinjiang sites and military-linked hospitals—raising biotech security concerns. The company also declared a routine $0.85 quarterly dividend and will support manufacturing of an experimental Ebola vaccine with up to $8.5 million in CEPI funding. The China probe introduces regulatory and reputational risk that could affect trial operations and market access. This follows a series of positive pipeline developments, including FDA approvals for Keytruda combinations and LIPFENDRA.
At the time of this announcement, MRK was trading at $129.50 on NYSE in the Life Sciences sector, with a market capitalization of approximately $322B. The 52-week trading range was $76.66 to $135.05. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.